AVE1625, a cannabinoid CB1 receptor antagonist, as a...

Psychopharmacology 2011 / 05 Vol. 215; Iss. 1

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

Mark D. Black, Rachel J. Stevens, Nancy Rogacki, Robert E. Featherstone, Yaw Senyah, Odessa Giardino, Beth Borowsky, Jeanne Stemmelin, Caroline Cohen, Philippe Pichat, Michal Arad, Segev Barak, Amaya
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
215
Language:
english
Pages:
15
DOI:
10.1007/s00213-010-2124-0
Date:
May, 2011
File:
PDF, 420 KB
english, 2011
Conversion to is in progress
Conversion to is failed